B+
Bull case
30%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-05-07 · RankAlpha Sentiment Codex
RFL
RafaelFNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that RFL now looks increasingly like a focused Trappsol Cyclo vehicle, with management explicitly prioritizing completion of the pivotal Phase 3 trial and an April 2026 MIT license that may support follow-on neurodegenerative optionality [#10-Q-2026-03-16][#8-K-2026-04-22].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Cash burn and clinical spending trends may force additional financing before full de-risking of the lead program.
Momentum
66
Value
41
Sentiment
13
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.20 · Bull $2.10 · Bear $0.70Analysis 2026-05-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum66 · Δ7d -
Value41 · Δ7d -0.0
Sentiment13 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Cash burn and clinical spending trends may force additional financing before full de-risking of the lead program.
- • The MIT Alzheimer license may remain early-stage optionality unless Rafael discloses a funded development path, economics, or regulatory timeline.
- • The bear case is that conviction still rests on one major readout, while cash declined to $37.8 million at January 31, 2026 and six-month operating cash burn accelerated, leaving financing and dilution risk meaningful if timelines slip or data disappoint [#10-Q-2026-03-16].
Catalyst clock
2026-08-31
Runway and financing scrutiny should rise as trial spend continues
Lead driver: Value · See fundamentals
Momentum
66
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
13
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 65.6 / Value 41.2 / Sentiment 13.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-07. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-05-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-05-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$97.26M
Beta
0.68
Shares Out
52M
P/E (TTM) · Derived
-1.8
P/S (TTM)
63.89
P/FCF (TTM) · Derived
-2.82
Rev YoY
-50.6%
EPS YoY
-55.8%
Gross Margin
+74.4%
Op Margin
-3717.2%
Net Debt
-$52.08M
Current Ratio
3.16
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data